Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions.  All of the Company's drug candidates are new molecular entities discovered internally by its dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. Lexicon Pharmaceuticals has advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome.

Company Growth (employees)
Type
Public
HQ
Spring, US
Founded
1995
Size (employees)
168 (est)+40%
Lexicon Pharmaceuticals was founded in 1995 and is headquartered in Spring, US

Key People at Lexicon Pharmaceuticals

Raymond Debbane

Raymond Debbane

Chairman of the Board
Pablo Lapuerta

Pablo Lapuerta

Executive Vice President of Clinical Development and Chief Medical Officer
Jeffrey L. Wade

Jeffrey L. Wade

Executive Vice President and Chief Financial Officer
James F. Tessmer

James F. Tessmer

Vice President of Finance and Accounting
Alan J. Main

Alan J. Main

Executive Vice President, Commercial Supply Operations
Lonnel Coats

Lonnel Coats

President and Chief Executive Officer and Director

Lexicon Pharmaceuticals Office Locations

Lexicon Pharmaceuticals has offices in Spring, The Woodlands, Boston, Philadelphia and in 27 other locations
Spring, US (HQ)
8800 Technology Forest Place
Show all (31)

Lexicon Pharmaceuticals Data and Metrics

Lexicon Pharmaceuticals Financial Metrics

Lexicon Pharmaceuticals's revenue was reported to be $18.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

18.3 m

Gross profit (Q1, 2017)

18.1 m

Gross profit margin (Q1, 2017), %

99%

Net income (Q1, 2017)

(34.9 m)

EBIT (Q1, 2017)

(42.5 m)

Market capitalization (25-Jul-2017)

1.8 b

Cash (31-Mar-2017)

2.5 m
Lexicon Pharmaceuticals's current market capitalization is $1.8 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.2 m22.9 m130 m83.3 m

Revenue growth, %

929%469%(36%)

Operating expense total

104.6 m123.2 m128.5 m220.5 m

EBIT

(102.4 m)(100.4 m)1.5 m(137.2 m)

EBIT margin, %

(4607%)(439%)1%(165%)

Interest expense

2 m2.3 m6.7 m6.6 m

Interest income

157 k2.3 m572 k2.3 m

Pre tax profit

(104.1 m)(100.4 m)(4.7 m)(141.4 m)

Net Income

(104.1 m)(100.3 m)(4.7 m)(141.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

676 k419 k1.8 m376 k566 k20.1 m27.7 m18.3 m

Cost of goods sold

225 k

Gross profit

18.1 m

Gross profit Margin, %

99%

EBIT

(26.1 m)(40.3 m)(26.5 m)(26.7 m)(33.7 m)(33.9 m)(37 m)(34.9 m)(42.5 m)

EBIT margin, %

(3863%)(9627%)(1480%)(7098%)(5950%)(184%)(126%)(232%)

Interest income

4 k5 k153 k269 k82 k637 k547 k564 k530 k

Net Income

(34.9 m)(73 m)(109 m)(34.9 m)
USDFY, 2013FY, 2014FY, 2015

Cash

37.5 m137.3 m46.6 m

Current Assets

134.6 m369 m357.9 m

Goodwill

44.5 m44.5 m44.5 m

Total Assets

274.2 m471.4 m475.6 m

Accounts Payable

9.7 m13.1 m52.9 m

Total Debt

21.9 m107.7 m101.4 m

Current Liabilities

19.3 m45 m164.6 m

Total Liabilities

318.2 m

Additional Paid-in Capital

1.2 b1.4 b1.4 b

Retained Earnings

(1 b)(1.1 b)(1.3 b)

Total Equity

170.2 m284 m157.4 m

Debt to Equity Ratio

0.1 x0.4 x0.6 x

Debt to Assets Ratio

0.1 x0.2 x0.2 x

Financial Leverage

1.6 x1.7 x3 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

9.7 m61.7 m24.7 m38.4 m38.8 m2.5 m

Inventories

236 k

Current Assets

313.8 m288.9 m492.2 m439.5 m398.7 m279.1 m

Goodwill

44.5 m44.5 m44.5 m44.5 m44.5 m44.5 m

Total Assets

416 m391.1 m611.3 m558.1 m516.9 m396.3 m

Accounts Payable

11.3 m16.4 m25.5 m28.2 m41.5 m41.9 m

Current Liabilities

43.6 m51.8 m121.9 m131 m170.1 m137.1 m

Additional Paid-in Capital

1.4 b1.4 b1.4 b1.4 b1.4 b1.4 b

Retained Earnings

(1.2 b)(1.2 b)(1.1 b)(1.2 b)(1.2 b)(1.3 b)

Total Equity

231.5 m197.9 m252.9 m217.3 m185.2 m134.6 m

Financial Leverage

1.8 x2 x2.4 x2.6 x2.8 x2.9 x
USDFY, 2013FY, 2014FY, 2015

Depreciation and Amortization

2.1 m

Accounts Receivable

(4.1 m)

Cash From Operating Activities

(91.1 m)(75.6 m)(175.6 m)

Purchases of PP&E

(1.7 m)(80 k)(231 k)

Cash From Investing Activities

99.5 m(108.4 m)18.3 m

Cash From Financing Activities

(1.4 m)283.8 m987 k

Interest Paid

1.9 m1.8 m6.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(34.9 m)(73 m)(109 m)(34.9 m)

Depreciation and Amortization

1.2 m1.7 m355 k601 k661 k521 k1 m1.5 m634 k

Accounts Receivable

509 k625 k865 k719 k963 k170 k(107 k)173 k(1.2 m)

Cash From Operating Activities

(50 m)(71.2 m)(23.5 m)(55.7 m)(81.1 m)(43.7 m)(91.6 m)(126.8 m)(85.5 m)

Purchases of PP&E

(39 k)(46 k)(17 k)(480 k)(664 k)(54 k)(67 k)(83 k)(92 k)

Cash From Investing Activities

41.8 m62.3 m(71 m)(70.7 m)7.1 m(133.6 m)(72.1 m)(38.2 m)42.5 m

Cash From Financing Activities

(1.6 m)(1.9 m)(830 k)(1.2 m)(1.6 m)(928 k)(857 k)827 k(1.1 m)

Interest Paid

896 k1.4 m412 k3.2 m3.6 m378 k3 m3.4 m332 k
USDY, 2017

Revenue/Employee

108.9 k

Financial Leverage

2.9 x

Lexicon Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials

1

Products

1

Phase Preclinical

1

Phase III Trials

2

Lexicon Pharmaceuticals Market Value History

Lexicon Pharmaceuticals Online and Social Media Presence

Lexicon Pharmaceuticals Company Life and Culture

You may also be interested in